SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-20-030289
Filing Date
2020-12-02
Accepted
2020-12-02 16:19:44
Documents
1
Period of Report
2020-11-30

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 2973
  Complete submission text file 0001127602-20-030289.txt   4345
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address 6300 DUMBARTON CIRCLE FREMONT CA 94555
Business Address
ASELAGE STEVE (Reporting) CIK: 0001221599 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 201364007